Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
Travere Therapeutics presented new Phase 3 PROTECT biomarker data at ASN Kidney Week 2026 showing FILSPARI achieved greater reductions in kidney inflammation and injury biomarkers than maximum-dose irbesartan in IgA nephropathy. At Week 110, sCD163 fell 60.1% with FILSPARI vs 26.0% with irbesartan, C5b-9 fell 50.2% vs 7.3%, and IL-6 fell 45.4% while rising 8.7% on irbesartan (all nominal p-values significant).
Key figures
- Drug Name
- FILSPARI (sparsentan)
- Phase Of Trial
- Phase 3
- Study enrollment
- 404
- Study duration weeks
- 110
- Il6 change irbesartan
- 8.7% increase
- Il6 reduction filspari
- 45.4%
- Baff reduction filspari
- 64.4%
- C5b9 reduction filspari
- 50.2%
- Baff reduction irbesartan
- 45.2%
- C5b9 reduction irbesartan
- 7.3%
- S CD163 reduction filspari
- 60.1%
- Biomarker analysis patients
- 295
- S CD163 reduction irbesartan
- 26.0%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.